Recursion Pharmaceuticals (RXRX) Change in Account Payables (2020 - 2026)

Recursion Pharmaceuticals has reported Change in Account Payables for 7 years, with the latest figure at $2.1 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Account Payables fell 43.93% year-over-year to $2.1 million; the trailing twelve-month figure through Mar 2026 stood at -$4.2 million (down 147.3% YoY), and the FY2025 full-year result was -$2.6 million, down 140.65% from the prior year.
• Change in Account Payables for Q1 2026 stood at $2.1 million, down from $4.4 million in the prior quarter.
• The five-year high for Change in Account Payables was $8.1 million in Q4 2024, with the low at -$5.9 million in Q3 2025.
• Historically, Change in Account Payables has averaged $392294.1 across 5 years, with a median of $695000.0 in 2022.
• Annual changes were most pronounced in 2022 — Change in Account Payables slumped 1488.73% — and 2024, when it jumped 2662.15%.
• Recursion Pharmaceuticals' Change in Account Payables stood at $695000.0 in 2022, then tumbled by 145.61% to -$317000.0 in 2023, then jumped by 2662.15% to $8.1 million in 2024, then plunged by 45.59% to $4.4 million in 2025, then slumped by 53.16% to $2.1 million in 2026.
• The last three Change in Account Payables figures came in at $2.1 million (Q1 2026), $4.4 million (Q4 2025), and -$5.9 million (Q3 2025), per Business Quant data.